Gara Jalqabaatti › Kanisa Harkaa › Texas › Houston
Qorannoo klinikaalii Kanisa Harkaa Houston, TX keessatti
Qorannoo 42 Kanisa Harkaa f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Namoota walitti qabaa jiraSadarkaa 2/3
- University of Texas MD Anderson Cancer Center, Houston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center - University of Texas, Houston
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UT MD Anderson Cancer Center, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Oncology Consultants, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Investigative Site #129, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of Texas MD Anderson cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Baylor St. Luke's Medical Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Qorannoo Kanisa Harkaa magaalota biroo keessatti
- Boston, MAQorannoo 32
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Baldwin Park, CAQorannoo 22
- Los Angeles, CAQorannoo 22
- Arlington, VAQorannoo 20
- Dallas, TXQorannoo 19
- San Antonio, TXQorannoo 19
- St. Louis, MOQorannoo 18
- Grand Rapids, MIQorannoo 18
- Washington, DCQorannoo 16
- Chicago, ILQorannoo 16
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.